WO2012175027A1 - Procédés de mutagenèse de schizochytrium sp et souches variantes produites par ces procédés - Google Patents
Procédés de mutagenèse de schizochytrium sp et souches variantes produites par ces procédés Download PDFInfo
- Publication number
- WO2012175027A1 WO2012175027A1 PCT/CN2012/077285 CN2012077285W WO2012175027A1 WO 2012175027 A1 WO2012175027 A1 WO 2012175027A1 CN 2012077285 W CN2012077285 W CN 2012077285W WO 2012175027 A1 WO2012175027 A1 WO 2012175027A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- schizochytrium
- variant
- dha
- naive
- Prior art date
Links
- 238000002703 mutagenesis Methods 0.000 title claims abstract description 13
- 231100000350 mutagenesis Toxicity 0.000 title claims abstract description 13
- 241000598397 Schizochytrium sp. Species 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 37
- 230000012010 growth Effects 0.000 claims abstract description 40
- ABOOPXYCKNFDNJ-UHFFFAOYSA-N 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenoxy}propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 ABOOPXYCKNFDNJ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 230000005855 radiation Effects 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000002028 Biomass Substances 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000012138 yeast extract Substances 0.000 claims description 12
- 229940041514 candida albicans extract Drugs 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 10
- 229940073490 sodium glutamate Drugs 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical group 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229940124238 Acetyl Coenzyme A carboxylase inhibitor Drugs 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 241000233671 Schizochytrium Species 0.000 abstract description 8
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 abstract description 6
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 164
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 82
- 229940090949 docosahexaenoic acid Drugs 0.000 description 82
- 239000002609 medium Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 150000002632 lipids Chemical class 0.000 description 10
- 108020004463 18S ribosomal RNA Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 231100000225 lethality Toxicity 0.000 description 6
- 241000003595 Aurantiochytrium limacinum Species 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000159660 Nannochloropsis oculata Species 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- OSUHJPCHFDQAIT-UHFFFAOYSA-N ethyl 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenoxy}propanoate Chemical group C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 OSUHJPCHFDQAIT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- -1 such as Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001104939 Nitzschia laevis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 238000012214 genetic breeding Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000009569 heterotrophic growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
- C12N15/03—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/12—Unicellular algae; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/12—Unicellular algae; Culture media therefor
- C12N1/125—Unicellular algae isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/89—Algae ; Processes using algae
Definitions
- the application relates to microbial genetic breeding technology and biological fermentation technology, particularly, a variant or mutant strain of microalgae for producing DHA (Docosahexaenoic acid).
- DHA Docosahexaenoic acid, C22:6, (omega-3)
- DHA is an essential fatty acid, i.e. a long-chain fatty acids which cannot be synthesized in human body and has important physiological functions.
- DHA is a main component in human brain and retina. 20% of the total DHA is present in cerebral cortex and up to 50% in retina. Therefore, it plays an important role in development of nervous system and visual system, and maintenance of normal intelligence and vision function.
- DHA also has physiological functions in prevention of cardiovascular diseases, cancers, inflammation, etc.
- it is also an essential fatty acid required by a variety of marine fishes for growth and development, and it can improve the survival rate of fish fries and reduce the incidence of albinism.
- DHA is obtained from fish oil.
- Schizochytrium sp. is a marine microalgae (or pseudo-fungi) that has been developed as a commercial source for producing DHA and other polyunsaturated fatty acids (PUFAs). The biosafety of Schizochytrium sp. has been verified. Hammond et al. performed a series of tests with it on rats and rabbits, and found no side effects.
- Acetyl-CoA carboxylase (ACC, (EC 6.4.1.2) is a key enzyme in fatty acid synthesis, and herbicide Quizalofop ⁇ 2-[4-(6-chloro-2-Quinoxaline-oxy)-phenoxy] propionate ⁇ is an inhibitor of this enzyme. In the presence of Quizalofop, cells grow slowly or even die due to the disturbed fatty acid biosynthesis.
- a Schizochytrium sp. variant or mutant with increased DHA content can be obtained by applying a mutagenesis of UV radiation to a Schizochytrium sp. strain and then performing a directional selection by using an inhibitor to the key enzyme in fatty acid synthesis (such as acetyl coenzyme A carboxylase), including but not limited to Quizalofop. Further, the obtained variants or mutants have high DHA contents, as well as improved growth rates compared with a naive Schizochytrium sp. strain.
- a method for producing a variant of Schizochytrium sp. strain having increased DHA content compared with a naive Schizochytrium sp. strain comprising inducing mutagenesis in a Schizochytrium sp. strain with UV radiation to produce a mutant strain; contacting the mutant strain with an acetyl coenzyme A carboxylase inhibitor; and selecting a variant of Schizochytrium sp. strain having increased DHA content compared with a naive Schizochytrium sp. strain.
- the inhibitor to acetyl coenzyme A carboxylase is Quizalofop.
- the selected variant having increased DHA content also has improved growth rate compared with that of a naive Schizochytrium sp. strain so that the efficiency of DHA production is increased compared with that of a naive Schizochytrium sp. strain.
- the variant of Schizochytrium sp. strain has higher DHA content as compared with that of its starting strain or a naive Schizochytrium sp. strain.
- the variant of Schizochytrium sp. strain has higher DHA content as compared with that of the starting or naive strain after UV radiation-induced mutagenesis with or without the selection by using an inhibitor to acetyl coenzyme A carboxylase.
- a variant of Schizochytrium sp. strain such as strain 2010-0321 with a deposit reference number of CCTCC M 2011024 as deposited at the Chinese Center for Type Culture Collection (CCTCC) on January 21, 2011.
- the variant strain provided herein has increased DHA content compared with that in a naive Schizochytrium sp. strain.
- the variant provided herein is obtained by the method as disclosed herein comprising inducing mutagenesis in a Schizochytrium sp. strain with UV radiation to produce a mutant strain, and contacting the mutant strain with an acetyl coenzyme A carboxylase inhibitor; and selecting a variant of the Schizochytrium sp. strain having increased DHA content and/or improved growth rate compared with a naive Schizochytrium sp. strain.
- a method for producing DHA comprising culturing a variant of Schizochytrium sp. strain as disclosed herein in a culture medium, and optionally comprising collecting DHA from a biomass of the cultured variant of Schizochytrium sp. strain, or a culture medium thereof. According to an embodiment, it is also related to biomass produced by this method.
- the food product contains the biomass (i.e. having increased concentration of DHA compared with a naive Schizochytrium sp. strain) or DHA produced according to the method disclosed herein.
- Figure 1 shows lethal effects of ultraviolet radiation on Schizochytrium sp.
- Figure 2 shows the relationship between the concentration of Quizalofop and corresponding lethality rate of Schizochytrium sp..
- Figure 3 shows the growth rates and DHA contents of a control strain (or a naive strain) and some variant strains.
- Figure 4 shows the growth rates and DHA contents of a control strain and three variants in a 50-liter fermentor experiment.
- Figure 5 shows alignment comparison of 18S rRNA sequences between a control strain and variant strain 2010-0321.
- strain refers to any culture, generally pure culture, of a microorganism such as algae or microalgae species including a Schhochytrium sp. strain obtained from a single cell or an isolated colony.
- the term 'Variant or “mutant” of a reference strain X refers to any strain obtained from the reference strain X.
- the term “variant” more particularly refers to a strain obtained mainly by mutation and selection performed on a reference strain X
- the term “mutant” more particularly refers to a strain obtained by random or directed mutagenesis (for example UV radiation) applied to a reference strain X.
- mutant or variant possesses the features according to various aspects disclosed herein, particularly a higher or increased DHA content compared with a naive algae or microalgae species, particularly a Schizochytrium sp. strain, it falls within the protection scope claimed in the application.
- food product refers to any product intended for supplying human or animals with nutrition.
- food products include products intended for feeding infants, children, adolescents and adults. All or part of the food products disclosed herein may contain at least one biomass or DHA obtained by the method disclosed herein.
- the food products disclosed herein may also contain other ingredients usually used in the agriculture or food industry, such as additives, preservatives, fruits or fruit extracts, flavouring agents, colorants, thickeners, cereals, chocolate, etc.
- the food product is a dairy product.
- the term "dairy product” refers to, in addition to milk, any product derived from milk, such as, milk powder, cream, ice cream, butter, cheese, yogurt, fermented milk, or by-products derived from milk, such as lactoserum and casein as well as various prepared food products containing milk or milk fractions as main ingredient.
- the milk is generally from cows, but can also be obtained from other mammals, such as a goat, a ewe, a mare, a camel or a buffalo.
- the dairy products incorporate the biomass or DHA produced according to the method disclosed herein.
- Microorganisms suitable for serving as a starting strain or a naive/control strain for the mutation mutagenesis and/or selection disclosed herein include heterotrophic microalgaes, including members of the genus Schizochytrium.
- a particular member of the genus Schizochytrium is Schizochytrium limacinum.
- Suitable organisms can be obtained from a number of public-available sources, including by collection from the natural environment.
- Schizochytrium sp. which can be used in the present application includes Schizochytrium limacinum SR21, Schizochytrium sp. (S8) (ATCC 20889), Schizochytrium sp.
- LC- M (ATCC 18915) and Schizochytrium limacinum IFO 32693 (Honda et Yokochi, Institute for Fermentation (IFO), Osaka, Japan).
- Schizochytrium limacinum SR21 or Schizochytrium limacinum IFO 32693 is preferred.
- any microorganism or any specific type of organism includes wild-type strains, mutant strains or recombinant strains.
- biomass refers to a culture or cells in culture medium of algae or microalgae species, such as a Schizochytrium sp. strain, a variant of a Schizochytrium sp. strain, etc. as disclosed herein.
- biomass refers to at least partially dewatered algal or microalgal culture, or dewatered culture.
- the term “about” or “approximately” when used in conjunction with a numerical value refers to any value within 1, 5 or 10% variability of the referenced number.
- a Schizochytrium sp. strain is exposed to ultraviolet radiation for about 10 to 140 sec (s), preferably about 20s to 120s, more preferably about 30s to 100s, and most preferably about 70s to 90s.
- a Schizochytrium sp. strain is exposed to ultraviolet radiation for a period of time selected from the group consisting of about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 and 90 seconds.
- the survived colonies are collected and used in the directional selection by an acetyl coenzyme A carboxylase inhibitor, such as Quizalofop.
- Quizalofop is added to a culture medium at a certain concentration in order to select a Quizalofop-resistant strain.
- concentration of Quizalofop used in the selection is in the range of about 5 ⁇ /L to about 100 ⁇ /L, or about 10 umol/L to about 90 umoVL, or about 50 ⁇ /L to 80 ⁇ /L in a culture medium.
- the concentration of Quizalofop is selected from the group consisting of about 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80 ⁇ /L in a culture medium.
- Quizalofop is Quizalofop-p
- the selection for Quizalofop-resistant Schizochytrium sp. colonies is conducted in a solid culture medium containing Quizalofop. Then, survived colonies are picked out from the solid culture medium and subsequently cultured in a liquid or semi-solid culture medium containing Quizalofop to verify the Quizalofop resistance.
- the selected Quizalofop-resistant colonies are further screened for increased growth rate and DHA content compared with a naive strain such as a Schizochytrium sp. strain.
- the Schizochytrium sp.variants obtained by the method disclosed herein comprising UV exposure and Quizalofop selection can produce a higher or increased amount of DHA as compared with a starting or naive Schizochytrium sp.strain.
- the Schizochytrium sp.variants obtained by the method disclosed herein comprising UV exposure and Quizalofop selection can produce a higher or increased amount of DHA as compared with a starting or naive Schizochytrium sp.strain.
- variant can produce an amount of DHA higher than that produced by the starting or naive strain by at least about 10, 20, 25, 30, 35, 40%, or by at least about 20, 25, 30, 35, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70% in a 3 to 7-day, or a 5-day culture or biomass.
- the amount of DHA produced by the Schizochytrium sp In an embodiment, the amount of DHA produced by the Schizochytrium sp.
- the growth rate of the selected Schizochytrium sp. variants are higher than those of the starting or naive strains by at least about 3, 4, 5, 6, 7, 8, 9 or 10%, preferably over a 3 to 7-day culture, more preferably over a 5-day culture.
- the selected Schizochytrium sp. variant strains have stable growth rate and ability to produce DHA at a high amount under different culture conditions, such as different concentrations of glucose, different nitrogen sources and different pH values as compared with those of the starting or naive strains.
- the 18S RNA of the Schizochytrium sp. variants can be analyzed to identify genetic variations as compared to the starting or naive strains.
- examples of the Schizochytrium sp. variants comprise but not limited to strains 321-1, 2010-0321, and 303-11, particularly strain 2010-0321.
- a Schizochytrium sp. variant disclosed herein particularly a strain selected from the group consisting of strains 321-1, 2010-0321, 303-11, and any combination thereof, or strain 2010-0321, is cultured under a cultivation condition suitable for culturing Schizochytrium sp. strains.
- the cultivation conditions may be established according to culturing methods well-known in the art, including the methods disclosed in U. S. Patent No. 5,130, 242 and U. S. Patent No. 7,022,512, which are incorporated herein by reference in their entirety, and optimal cultivation conditions may be readily determined by those skilled in the art.
- cultivation may be carried out in any suitable fermentor, such as a stirred tank fermentor or an air-lift fermentor which provides oxygen source.
- the microorganisms can be agitated at a certain level, such that the concentration of dissolved oxygen is sufficient to support the growth of the culture and production of DHA, and at the same time the agitation does not shear or otherwise damage the microorganisms.
- Suitable level of dissolved oxygen is at least 10% of air saturation level. More particularly, level of dissolved oxygen is maintained from about 10% to about 50% of air saturation levels.
- An exemplary fermentor used in the method disclosed herein may provide an aeration rate of 1 WM with a rotating speed of about 70-100 rpm.
- the capacity of the fermentor is at least 10-60 liters, such as 10, 20, 30, 40, 50 or 60 liters.
- a fermentor with the capacity of up to 100 or even 150 liters can be used.
- Cultivation may be carried out at any temperature suitable for maintaining the survival of microorganisms.
- microorganisms may be cultured at a temperature from about 15°C to about 34°C.
- the cultivation temperature is maintained at about 20°C to about 28°C, more preferably about 22°C to about 27°C.
- the pH of the culture medium during fermentation can be from 4 to 10, such as from 5 to 8, preferably from 6 to 7.
- the fermentation will last for 10 days or less, or 9 days or less, or 8 days or less.
- the fermentation duration may be or be at least 3, 4, 5, 6 or 7 days.
- the fermentation duration may be 150 to 200 hours, such as 160 to 190 hours, or from 170 to 180 hours.
- medium used in the method for culturing the Schizochytrium sp. variants disclosed herein is a liquid medium, which may comprise the components that can promote growth and production of DHA at commercially practicable scales, including those components disclosed in U. S. Patent No. 5,130, 242 and U. S. Patent No. 7,022, 512, all of which are incorporated herein by reference in their entirety.
- the medium used for culturing the Schizochytrium sp. variants disclosed herein to produce DHA comprise a carbon source, and an organic or inorganic nitrogen source.
- the carbon source comprises glucose, various starches, molasses, ground corn or a combination thereof.
- the nitrogen source may include but not limited to nitrate, urea, ammonium salts, amino acids, yeast extracts and the like.
- An assimilable phosphorous (e.g. phosphate) and/or sulphur (e.g. sulphate) source may also be provided in the medium.
- the medium may additionally contain other substances to facilitate the fermentation, for example a chelating agent (e.g. citric acid), an anti-foaming agent (e.g. soy bean oil), a vitamin (e.g. thiamine and or riboflavin), essential catalytic metals (for example, alkali earth metals such as magnesium or calcium, or zinc or iron and/or other metals such as cobalt and copper).
- a chelating agent e.g. citric acid
- an anti-foaming agent e.g. soy bean oil
- a vitamin e.g. thiamine and or riboflavin
- essential catalytic metals for example, alkali earth metals such as magnesium or calcium, or zinc or iron and/or other metals such as cobalt and copper.
- the medium also may contain a source of microbial growth factors, which are unspecified or specified compounds that can enhance the heterotrophic growth of unicellular microorganisms.
- Exemplary medium for culturing Schizochytrium sp. may be found in Jiang and Chen, Process Biochemistry 35 (2000) 1205-1209; Jiang and Chen, Journal of Industrial Microbiology & Biotechnology, (1999) Vol. 23,508-513 ; Vazhappilly and Chen, Journal of the American Oil Chemists Society, (1998) Vol. 75, No. 3 p 393-397.
- the medium used in the method disclosed herein contains glucose 40-60, yeast extract 10-15, glutamic acid 4-8, sodium chloride 2.4-4.0, bitter salt 3.0-6.0, and ammonia sulfate 3.0-6.0 (g/L medium).
- the medium used in the methods disclosed herein consists of glucose 40-60, yeast extract 10-15, sodium glutamate 4-8, sodium chloride 2.4-4.0, bitter salt 3.0-6.0, and ammonia sulfate 3.0-6.0 (g L medium).
- An example of the medium used herein consists of glucose 60.0, yeast extract 15.0, sodium glutamate 4.0, sodium chloride 3.0, bitter salt 5.0, and ammonia sulfate 5.0 (g L medium).
- the organisms or biomass may be harvested by means, such as centrifugation, flocculation, or filtration, and can be processed immediately or dried for future processing.
- lipids can be extracted.
- the term "lipid” includes phospholipids; free fatty acids; esters of fatty acids; triacylglycerols; diacylglycerides; monoacylglycerides; lysophospholipids; soaps; phosphatides; sterols and sterol esters; carotenoids; xanthophylls (e.g., oxycarotenoids); hydrocarbons; and other lipids known to one of ordinary skill in the art.
- DHA disclosed herein can be in the form of these various lipids, and is not limited to a free fatty acid, which may be a form in the food product disclosed herein. Different forms or fractions of the lipids can be extracted, depending on the extraction technique that is used.
- Lipids can be extracted with an effective amount of solvent.
- suitable solvents used in the extraction polar lipids (e.g., phospholipids) are generally extracted with polar solvents (e.g., chloroform/methanol), and neutral lipids (e.g., triacylglycerols) are generally extracted with non-polar solvents (e.g., hexane).
- a particular solvent is pure hexane.
- a suitable ratio of hexane to dry biomass is about 4 liters of hexane per kilogram of dry biomass.
- hexane is mixed with the biomass in a stirred reactor at a temperature of about 50°C for about 2 hours.
- the biomass is filtered and separated from the oil-containing hexane.
- Hexane is removed from the oil by distillation techniques.
- Conventional oilseed processing equipment is suitable to perform the filtering, separation and distillation. Additional processing steps can be performed if required or desirable for a particular application.
- Schizochytrium limacimim SR21 which was also used as a control or naive strain in the following Examples, was plated onto dishes, and exposed to UV radiation for 0 sec (control), 30 sec, 40 sec, 50 sec, 60 sec, 70 sec, 80 sec, 90 sec and 100 sec (experimental groups), respectively. After radiation, the dishes were kept in dark for 24h, and the numbers of colonies on each dish was counted. The number of colonies in the control group was defined as 100%, and a lethality rate in each experimental group was calculated accordingly (Figure 1). As shown in Figure 1, with prolonged radiation duration, higher lethality rate was observed in Schizochytrium sp., indicating a dose-dependent effect. Particularly, a radiation duration of 70-90 sec, which resulted in a lethality rate of 60%-80% in Schizochytrium sp., was used to induce mutagenesis in Schizochytrium sp..
- the culture conditions are: A. culture medium consisting of
- Quizalofop ethyl was added into the medium for culturing Schizochytrium sp. at a concentration of 0 umol/L, 10 ⁇ mol/L, 30 ⁇ L, 50 ⁇ /L, 70 ⁇ L, 80 ⁇ /L and 90 umol/L.
- the number of colonies in the control group (0 ⁇ /L) was defined as 100%. Colonies in each group were counted, and the lethality rates were calculated based on the number of colonies in the control group ( Figure 2). As shown in Figure 2, within the experimental range, a positive correlation between the lethality rates of Schizochytrium sp. and the concentrations of Quizalofop was observed.
- the concentration of Quizalofop used for selecting resistant strains was set to 50 ⁇ L to 80 ⁇ L.
- the selected strains may be cultured in a liquid or semi-solid Quizalofop-containing medium to validate their Quizalofop resistance.
- the culture conditions are:
- A. culture medium consisting of
- Example 3 Differences between naive strains and variant strains in growth rate and DHA content
- the culture conditions are:
- A. culture medium consisting of
- Figure 3 shows the biomass and DHA content of the control strain (left most) and some of the variants which underwent UV mutagenesis followed by Quizalofop selection.
- some of the mutant strains had growth rate and the DHA content lower than that of the control strain, e.g. 321-6, 321-7 and 321-8, and some had growth rate and the DHA content not significantly different from that of the control strain, e.g. 321-4 321-5 and 321-19.
- many of them had increased DHA content, e.g. 321-1, 2010-0321, 321-12, 321-13, 321-14, 321-15, 321-16, 321-17 and 321-18.
- the outstanding strains are 321-1 and 2010-0321, which had growth rate increased by 10.5% and 31.5%, and DHA content increased by 64.5% and 66.4%, respectively.
- mutant strain 303-11 In addition to these two mutant strains, mutant strain 303-11 also showed good growth rate and DHA content.
- strains 2010-0321, 321-1 and 303-11 were selected for the tests as described in Examples 4-7 to verify that the variants obtained by the method of the application had the properties of high DHA content and growth rate, and the above properties could be stably maintained under different culture conditions.
- A. culture medium consisting of
- Example 4 The growth rates and DHA contents of the control strain and strains 321-1, 2010-0321 and 303-11 cultured under different concentrations of glucose.
- the culture conditions are the same as those in the general conditions as described above.
- g L.d weight of biomass per liter of medium per day.
- w/w% percentage of weight of DHA based on weight of dry cells.
- Example 5 Growth rate and DHA content of the control strain and strains 321-1, 20104)321 and 303-11 cultured in different nitrogen sources
- the culture conditions are the same as the general conditions as described above.
- the Example was conducted to compare the growth rate and DHA content of the control (naive) strain and mutant strains 321-1, 2010-0321 and 303-11 cultured in different nitrogen sources.
- the nitrogen source in the initial medium was replaced by following nitrogen sources: (a) Yeast extract (20 g L); (b) Yeast extract (20 g L)+Sodium glutamate (10 g LXc) Yeast extract(40 g L)+Sodium glutamate (10 g/L), and (d) Corn syrup(40 g/L)+Sodium glutamate (10 g L).
- mutant strains 321-1 and 2010-0321 were superior to those of the control strain, in which strain 2010-0321 was better than strain 321-1 in DHA content, while strain 303-11 showed a higher DHA content as compared to the control strain.
- w/w% percentage of weight of DHA based on weight of dry cells.
- Example 6 Growth rate and DHA content of the control strain and strains 321-1, 2010-0321 and 303-11 cultured under different pH values
- the culture conditions are the same as those in the general conditions as described above.
- g L.d weight of biomass per liter of medium per day.
- w/w% percentage of weight of DHA based on weight of dry cells.
- Example 7 Growth rate and DHA content of the control strain and strains 321-1, 2010-0321 and 303-11 cultured in 50-L fermentors
- Example 7 was conducted to assess the growth rate and DHA accumulation of the control (naive) strain and strains 321-1, 2010-0321 and 303-1 Icnltured in 50-L fermentors ( Figure 4).
- the strains were cultured under the general conditions as described above.
- strain 321-1 showed biomass increased by 9.5% and DHA content increased by 16.7%, respectively.
- strain 2010-0321 the biomass and DHA content increased by 6.7% and 48.1%, respectively.
- the biomass was substantially the same as the control strain, and the DHA content increased by only 7.9%.
- 2010-0321 was most prominent, particularly in term of DHA content.
- Table 4 and Table 5 showed the differences between the control (naive) strain and strain 2010-0321 in biochemical composition, including the composition of proteins, amino acids and fatty acids.
- the content of proteins was determined by Kjeldahl method.
- the content of amino acids was assayed by an amino acid analyzer.
- the content of fat was analyzed by a lipid analyzer.
- strain 2010-0321 had protein content (23.8%) higher than mat of the control strain (22.3%). Consistently, strain 2010-0321 showed a higher level than the control strain in term of the content of most of the amino acids.
- strain 2010-0321 had remarkable differences from the control strain in the composition of fatty acids. Firstly, strain 2010-0321 had C16:0 content (8.2%) higher than that of the control strain (7.7%). Secondly, CI 6:1 was absent in 2010-0321, while the CI 6:1 content of the control strain was 1.0%. Thirdly, strain 2010-0321 had DHA (C22:6) content significantly higher than that of the control strain.
- the 18S rRNA gene of the control strain (SEQ ID NO: 1) is 1757 bp in length, while the 18S rRNA gene of strain 2010-0321 (SEQ ID NO: 2) is 1751 bp in length, in which 9 base pairs varied.
- the percent homology between the 18S rRNA gene of the control strain and that of strain 2010-0321 was 99%.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Botany (AREA)
- Plant Pathology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pediatric Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137033914A KR20140019840A (ko) | 2011-06-23 | 2012-06-21 | 스키조키트리움 종의 돌연변이유발 방법 및 이의 생성되는 변이체 균주 |
CN201280029881.9A CN103827289B (zh) | 2011-06-23 | 2012-06-21 | 裂殖壶菌诱变方法及其产生的变异株 |
JP2014516178A JP5894666B2 (ja) | 2011-06-23 | 2012-06-21 | シゾキトリウム属(Schizochytrium sp.)の突然変異誘導の方法及びそれから産生された変異体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110176833XA CN102839129A (zh) | 2011-06-23 | 2011-06-23 | 一种裂殖壶菌诱变方法及其产生的变异株 |
CN201110176833.X | 2011-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012175027A1 true WO2012175027A1 (fr) | 2012-12-27 |
Family
ID=47366849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/077285 WO2012175027A1 (fr) | 2011-06-23 | 2012-06-21 | Procédés de mutagenèse de schizochytrium sp et souches variantes produites par ces procédés |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5894666B2 (fr) |
KR (1) | KR20140019840A (fr) |
CN (3) | CN102839129A (fr) |
WO (1) | WO2012175027A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3001736A1 (fr) * | 2013-02-06 | 2014-08-08 | Roquette Freres | Biomasse de la microalgue schizochytrium mangrovei et son procede de preparation |
EP2947141A4 (fr) * | 2013-01-18 | 2016-08-10 | Kyowa Hakko Bio Co Ltd | Micro-organismes produisant de l'acide docosahexaénoïque et leur utilisation |
FR3038914A1 (fr) * | 2015-07-17 | 2017-01-20 | Fermentalg | Biomasse de thraustochytrides, procede de culture et utilisations |
FR3038913A1 (fr) * | 2015-07-17 | 2017-01-20 | Fermentalg | Biomasse de thraustochytrides, procede de culture et utilisations |
CN108587916A (zh) * | 2018-05-23 | 2018-09-28 | 昆明理工大学 | 一种共培养单针藻在中性条件下快速絮凝的方法 |
WO2022124482A1 (fr) * | 2020-12-07 | 2022-06-16 | 씨제이제일제당(주) | Procédé de production de biomasse comprenant une protéine et des acides gras oméga-3 à partir de microalgues uniques, et biomasse produite par ce procédé |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104450529A (zh) * | 2013-09-25 | 2015-03-25 | 郭星 | 一种裂殖壶菌菌株及其诱变方法和应用 |
CN104312929B (zh) * | 2014-10-27 | 2017-10-17 | 山东百龙创园生物科技股份有限公司 | 一株高产dha裂殖壶菌菌株及其培养方法与应用 |
FR3031984B1 (fr) * | 2015-01-27 | 2019-05-24 | Roquette Freres | Procede d'enrichissement de la biomasse de microalgues du genre traustochytrium en dha et en acides amines arg et glu |
CN105558305B (zh) * | 2015-12-10 | 2019-12-03 | 新奥科技发展有限公司 | 裂殖壶菌突变株及其应用 |
CN108220167A (zh) * | 2018-04-10 | 2018-06-29 | 中盐工程技术研究院有限公司 | 盐藻纯化分离方法及微藻纯化分离方法 |
CN108707630B (zh) * | 2018-06-12 | 2020-10-16 | 厦门大学 | 一种提高裂殖壶菌中epa含量的调控方法与应用 |
CN112481348A (zh) * | 2019-09-11 | 2021-03-12 | 天津大学青岛海洋技术研究院 | 一种高产dha裂殖壶菌突变菌株的筛选方法 |
CN111235035A (zh) * | 2019-12-30 | 2020-06-05 | 嘉必优生物技术(武汉)股份有限公司 | 一种裂殖壶菌突变株及其用于制备二十二碳六烯酸油脂的方法和应用 |
CN114164122B (zh) * | 2021-12-02 | 2023-06-20 | 嘉必优生物技术(武汉)股份有限公司 | 一种高产epa的裂殖壶菌及其应用 |
CN114621983B (zh) * | 2022-05-13 | 2022-08-16 | 南京师范大学 | 提高裂殖壶菌的dha产量的方法和微生物油脂的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101591617A (zh) * | 2009-06-15 | 2009-12-02 | 南京工业大学 | 一种二十二碳六烯酸生产菌株及其诱变筛选方法和其应用 |
CN101892160A (zh) * | 2010-01-06 | 2010-11-24 | 吉林省希玛生物科技有限公司 | 一种海洋真菌裂殖壶菌(Schizochytrium)LX0809及其工业应用 |
CN101914581A (zh) * | 2010-07-27 | 2010-12-15 | 南京工业大学 | 一种提高多烯不饱和脂肪酸发酵产量的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264967C (zh) * | 2004-12-08 | 2006-07-19 | 中国海洋大学 | 海洋真菌裂殖壶菌ouc88的工业应用 |
JP4344827B2 (ja) * | 2005-11-28 | 2009-10-14 | 国立大学法人九州大学 | スキゾキトリウム属の微生物を用いた長鎖高度不飽和脂肪酸含有リン脂質の製造方法 |
WO2008129358A2 (fr) * | 2006-08-01 | 2008-10-30 | Ocean Nutrition Canada Ltd. | Microbes produisant des huiles et procedes de modification associes |
KR20080111586A (ko) * | 2007-06-19 | 2008-12-24 | 이정열 | Schizochytrium mangrovei MM103을 이용한 Docosahexanoic acid(DHA)의 생산 방법 |
-
2011
- 2011-06-23 CN CN201110176833XA patent/CN102839129A/zh active Pending
-
2012
- 2012-06-21 CN CN201610685393.3A patent/CN106244576A/zh active Pending
- 2012-06-21 CN CN201280029881.9A patent/CN103827289B/zh not_active Expired - Fee Related
- 2012-06-21 KR KR1020137033914A patent/KR20140019840A/ko not_active Application Discontinuation
- 2012-06-21 JP JP2014516178A patent/JP5894666B2/ja not_active Expired - Fee Related
- 2012-06-21 WO PCT/CN2012/077285 patent/WO2012175027A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101591617A (zh) * | 2009-06-15 | 2009-12-02 | 南京工业大学 | 一种二十二碳六烯酸生产菌株及其诱变筛选方法和其应用 |
CN101892160A (zh) * | 2010-01-06 | 2010-11-24 | 吉林省希玛生物科技有限公司 | 一种海洋真菌裂殖壶菌(Schizochytrium)LX0809及其工业应用 |
CN101914581A (zh) * | 2010-07-27 | 2010-12-15 | 南京工业大学 | 一种提高多烯不饱和脂肪酸发酵产量的方法 |
Non-Patent Citations (4)
Title |
---|
CHENG CHEN: "Study on producing DHA by fermentation with Schizochytrium limacinum SR21", CHINESE MASTER'S THESES FULL-TEXT DATABASE (ENGINEERING SCIENCE AND TECHNOLOGY 1), no. 2, 15 August 2007 (2007-08-15) * |
DATABASE GENBANK 10 August 2010 (2010-08-10), LI,Q.: "Schizochytrium limacinum isolate OUC101 18S ribosomal RNAgene, partial sequence", accession no. M042905 * |
KAIMIN CAI: "Mutation breeding ofSchizochytrium limacinum and optimization of its fermentation conditions", CHINESE MASTER'S THESES FULL-TEXT DATABASE (ENGINEERING SCIENCE AND TECHNOLOGY I), 15 September 2008 (2008-09-15) * |
WEI PING ET AL.: "Effect of reinforcing acetyl-CoA supply in docosahexaenoic acid production by chizochytrium sp.", CHINA BIOTECHNOLOGY, vol. 31, no. 4, 26 April 2011 (2011-04-26), pages 87 - 91 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2947141A4 (fr) * | 2013-01-18 | 2016-08-10 | Kyowa Hakko Bio Co Ltd | Micro-organismes produisant de l'acide docosahexaénoïque et leur utilisation |
US10023884B2 (en) | 2013-01-18 | 2018-07-17 | Kyowa Hakko Bio Co., Ltd. | Microorganism producing docosahexaenoic acid and utilization thereof |
FR3001736A1 (fr) * | 2013-02-06 | 2014-08-08 | Roquette Freres | Biomasse de la microalgue schizochytrium mangrovei et son procede de preparation |
WO2014122158A1 (fr) * | 2013-02-06 | 2014-08-14 | Roquette Freres | Biomasse de la microalgue schizochytrium mangrovei et son procédé de préparation |
US9816116B2 (en) | 2013-02-06 | 2017-11-14 | Roquette Freres | Biomass of the microalgae Schizochytrium mangrovei and method for preparing same |
FR3038914A1 (fr) * | 2015-07-17 | 2017-01-20 | Fermentalg | Biomasse de thraustochytrides, procede de culture et utilisations |
FR3038913A1 (fr) * | 2015-07-17 | 2017-01-20 | Fermentalg | Biomasse de thraustochytrides, procede de culture et utilisations |
WO2017012933A1 (fr) * | 2015-07-17 | 2017-01-26 | Fermentalg | Biomasse de thraustochytrides enrichie en huiles et en proteines, procede de culture et utilisations |
WO2017012931A1 (fr) * | 2015-07-17 | 2017-01-26 | Fermentalg | Biomasse de thraustochytrides riche en proteines, procede de culture et utilisations |
CN108587916A (zh) * | 2018-05-23 | 2018-09-28 | 昆明理工大学 | 一种共培养单针藻在中性条件下快速絮凝的方法 |
WO2022124482A1 (fr) * | 2020-12-07 | 2022-06-16 | 씨제이제일제당(주) | Procédé de production de biomasse comprenant une protéine et des acides gras oméga-3 à partir de microalgues uniques, et biomasse produite par ce procédé |
Also Published As
Publication number | Publication date |
---|---|
CN106244576A (zh) | 2016-12-21 |
CN103827289B (zh) | 2017-07-21 |
CN102839129A (zh) | 2012-12-26 |
CN103827289A (zh) | 2014-05-28 |
JP5894666B2 (ja) | 2016-03-30 |
KR20140019840A (ko) | 2014-02-17 |
JP2014522635A (ja) | 2014-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012175027A1 (fr) | Procédés de mutagenèse de schizochytrium sp et souches variantes produites par ces procédés | |
CA2076018C (fr) | Acide docosahexenoique; methode de preparation et compositions | |
US9476075B2 (en) | Oil enriched with arachidonic acid of microorganisms (unicellular fungus Mortierella alpina) and method for the production thereof | |
Fan et al. | Production of high-value products by marine microalgae thraustochytrids | |
JP2006345866A (ja) | アラキドン酸の生成方法 | |
KR102534491B1 (ko) | Dha 및, arg 및 glu 아미노산을 갖는, 트라우스토키트리움 속 미세조류 바이오매스의 농축 방법 | |
EP2954072B1 (fr) | Biomasse de la microalgue schizochytrium mangrovei et son procédé de préparation | |
CN103882071B (zh) | 一种微生物油及其制备方法 | |
US20210030024A1 (en) | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs | |
EP3407729A1 (fr) | Biomasse de matière contenant des protéines et procédés de production | |
WO2020054804A1 (fr) | Procédé de production d'ester d'acide gras à nombre impair, et composition de culture | |
JP6429162B1 (ja) | ラビリンチュラ類の培養方法 | |
CN113678942B (zh) | 小球藻的应用 | |
JP2024087087A (ja) | 奇数脂肪酸エステルを含む培養組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12802374 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20137033914 Country of ref document: KR Kind code of ref document: A Ref document number: 2014516178 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12802374 Country of ref document: EP Kind code of ref document: A1 |